Over the long, checkered history of weight-loss drugs, a safe and highly effective medication has been the elusive holy grail. The handful of drugs currently approved for long-term treatment of obesity have a good safety profile and help people lose an average of about 5% to 10% of their body weight—a clinically meaningful amount but far from the results seen with bariatric surgery, the gold standard. That’s why, when weight-loss results for the drug semaglutide started to come in, “we all said, ‘Wow—game changing,’” Robert Kushner, MD, recalled in a recent interview with JAMA.
Abbasi J. Semaglutide’s Success Could Usher in a “New Dawn” for Obesity Treatment. JAMA. 2021;326(2):121–123. doi:10.1001/jama.2021.10307
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: